Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06204406Recruiting
Kidney-sparing treatment for upper tract urothelial cancer
This study looks at how well patients do when they have kidney-sparing treatment (instead of complete kidney removal) for upper tract urothelial carcinoma. It helps doctors understand which patients can safely avoid losing their kidney.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT06277791RecruitingPhase 2
Adebrelimab plus chemo before surgery for advanced oral cancer
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hubei, WuhanAges 18–75 - NCT06737913RecruitingPhase 2
Study of adebrelimab and bevacizumab with liver chemo for advanced liver cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Lanzhou, GansuAges 18 years+ - NCT07457281RecruitingPhase 1
A new drug combo for head and neck cancer before surgery
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
ChengduAges 18–70 - NCT06766266RecruitingPhase 1
Irinotecan and Epirubicin for recurring bladder cancer
This trial tests a combination of two chemotherapy drugs (irinotecan and epirubicin) for people whose bladder cancer has come back after prior treatment with a similar drug. The goal is to see if this combination can help shrink or control the cancer.
ChongqingAges 18 years+ - NCT07606508Recruiting
Tracking skin cancer patients starting systemic treatment
This study follows patients newly diagnosed with cutaneous squamous cell carcinoma (a type of skin cancer) who are beginning systemic treatment (medicine that affects the whole body). Researchers want to understand how these treatments work and track patient outcomes over time.
AmiensAges 18 years+ - NCT04888429RecruitingPhase 2
Check immunotherapy plus targeted pills for advanced lung sarcomatoid cancer
This Phase 2 trial tests two medicines (an immunotherapy drug and a targeted pill) to treat advanced or metastatic pulmonary sarcomatoid carcinoma. It may help shrink tumors and control the cancer, and it also collects tumor samples to study biomarkers.
Xiamen, FujianAges 18–75 - NCT07251413RecruitingPhase 1/Phase 2
Cemiplimab plus imiquimod and laser before surgery for basal cell carcinoma
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
Barcelona, BarcelonaAges 18 years+ - NCT07524452RecruitingPhase 3
Becotatug vedotin plus immunotherapy for head and neck cancer
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
Zhuhai, GuangdongAges 18–75 - NCT07371234RecruitingPhase 2
Low-dose radiation and immunotherapy before surgery for head and neck cancer
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
GuangdongAges 18–75 - NCT06288191RecruitingPhase 2
Nivolumab and relatlimab before surgery for skin cancer
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
Wollstonecraft, New South WalesAges 18 years+ - NCT06254248RecruitingPhase 2
Safety of two cancer drugs after liver transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
ClichyAges 18–90 - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT02491099RecruitingPhase 2
Afatinib for recurring HER2-positive uterine cancer
This trial tests afatinib, a targeted pill, in people whose uterine serous cancer has a specific HER2 (HER2/neu) tumor marker. It aims to shrink tumors or control the cancer when it keeps coming back.
Tucson, ArizonaAges 18–100 - NCT05062005RecruitingPhase 3
Tests two ways of treating locally advanced nasopharyngeal cancer
This phase 3 trial compares a standard treatment plan (CRT) versus a new approach (ICCRT) for people with locally advanced nasopharyngeal cancer, without spread to distant organs. It aims to see which plan works better and is safe for tumors in the head and neck area.
Guangzhou, GuangdongAges 18–65 - NCT06738251RecruitingPhase 3
Study of SHR-A2102 for advanced bladder cancer
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT07213557RecruitingPhase 2
Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Naples, ItaliaAges 18 years+ - NCT07099547RecruitingPhase 2
ZG005 plus chemo for advanced gallbladder cancer
This trial tests a new drug called ZG005 combined with standard chemotherapy for people with advanced gallbladder cancer. The goal is to see if adding ZG005 helps shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT06715501Enrolling by invitation
Testing cadonilimab with chemo and radiation for advanced esophageal cancer
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
Ningbo, ZhejiangAges 18–75 - NCT05860868RecruitingPhase 3
Two versus three chemo treatments before radiation for nasopharyngeal cancer
This Phase 3 trial compares giving two cycles versus three cycles of chemotherapy before other treatment for locally advanced nasopharyngeal cancer. It may help find which schedule works best to control the cancer while managing side effects.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT07536789RecruitingPhase 2
Testing MRG003 for Advanced Liver Cancer After Prior Treatment
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04910347RecruitingPhase 2
Nivolumab after chemoradiation for advanced nasopharyngeal cancer
This trial tests nivolumab (an immune system–boosting antibody) given after standard chemoradiation to help keep advanced nasopharyngeal cancer from coming back or progressing. It may help your immune system better find and attack cancer cells after treatment.
SeoulAges 19 years+ - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,164 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.